From: Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients
serum (μg/mL) | ascitic fluid (μg/mL) | percentage of serum in ascitic fluid | ||||
---|---|---|---|---|---|---|
TTR | RBP | TTR | RBP | TTR | RBP | |
Healthy control n = 20 | 363.3 ± 105.5 | 55.8 ± 9.3 | - | - | - | - |
All Stages ovarian cancer | 148.5 ± 96.7 | 22.5 ± 14.8 | 1.022 ± 0.239 | 4.632 ± 1.572 | 1.0 ± 0.6 | 26.2 ± 14.9 |
Stage I/II ovarian cancer | 162.5 ± 69.4 | 34.2 ± 22.3 | 0.966 ± 0.375 | 3.580 ± 0.849 | 0.8 ± 0.6 | 14.5 ± 9.8 |
Stage III ovarian cancer | 155.6 ± 107.6 | 19.5 ± 7.5 | 1.074 ± 0.185 | 4.800 ± 1.711 | 1.0 ± 0.6 | 27.2 ± 11.8 |
Stage IV ovarian cancer | 129.0 ± 96.0 | 17.4 ± 7.3 | 0.965 ± 0.241 | 4.627 ± 1.672 | 1.2 ± 0.7 | 32.1 ± 23.3 |
Ovarian cancer CRP > 40 mg/l | 116.0 ± 94.3 | 14.2 ± 4.3 | 1.047 ± 0.213 | 4.736 ± 1.886 | 1.4 ± 0.7 | 35.4 ± 17.2 |
Ovarian cancer CRP < 40 mg/l | 166.3 ± 92.1 | 24.1 ± 12.5 | 1.005 ± 0.260 | 4.503 ± 1.415 | 0.8 ± 0.5 | 22.3 ± 11.1 |